Reviewer’s report

Title: OXYTOCIN AND CARDIOPROTECTION IN DIABETES AND OBESITY

Version: 0 Date: 29 Mar 2016

Reviewer: James Blevins

Reviewer’s report:

The authors have presented an excellent overview of the role of oxytocin on cardioprotection in diabetes and obesity. I only have minor comments:

1) Abstract, line 1: The authors should be consistent over the abbreviation for OT throughout the manuscript

2) Background, line 17: the authors could also reference that oxytocin is also synthesized in parvocellular paraventricular nucleus neurons

3) Background, line 33: The authors could state how much affinity towards OTR relative to the AVP receptors

4) Pg. 6, line 17: mechanisms

5) Pg. 8, line 12: the authors could add Blevins et al., Am. J. Physiol., 2016 (in press)

6) Pg. 8, line 9: The references to genetic models of obesity could also be included (Gajdosechova et al., 2014, and Plante et al., 2015)

7) Pg. 8, line 29: the authors could also mention that intranasal OT may also increase OT levels in the circulation if the intranasal delivery device did not sufficiently target the drug to the cribiform plate (reviewed in Meredith, ME et al., AAPS, 2015)

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal